AbbVie Netherlands 2016 Transparency Disclosure Methodological Notes

Ensuring compliance with the legal requirement by **the Ministry of Health and the code on regulations of medicine promotions (the CGR)** AbbVie Netherlands will publish Transfer of Value (ToV) to HCPs and HCOs according to the local law on the platform http://transparantieregister.nl/nl-NL/Zoeken-in-het-register/Big-nummer.

As a member company of NEFARMA, R&D transactions have to be disclosed on an aggregated level for the calendar year 2016.

This Methodological Note provides guidance on how Abbvie Netherlands has recorded and publicly reported this information in accordance with the current editions of NEFARMA Disclosure Code for R&D disclosure.

Reporting period / Reportable ToV:
The AbbVie Netherlands 2016 disclosure includes applicable ToVs provided between 1 January 2016 and 31 December 2016 related to 2016 events. Transactions processed after the 2015 cut-off date may be included in the 2016 report.

Transactions processed after February 10, 2017 will be considered for the next report.

Cross borders interactions:
AbbVie affiliates (worldwide) that have provided The Netherlands HCPs/HCOs with a reportable ToV have been included.

Research and Development:
For the purpose of disclosure, research and development (R&D) ToVs are ToVs to HCPs or HCOs related to the planning or conduct of:

- non-clinical studies
- clinical trials
- non-interventional studies that are prospective in nature and involve the collection of data from, or on behalf of, individual or groups of HCPs specifically for the study.

The total aggregate disclosure includes transfers of value made by AbbVie Netherlands to HCOs, as well as those made by its parent company, subsidiaries and joint ventures.

Clinical trials with retrospective elements, including ToVs direct or indirect to HCOs, has been disclosed at an individual level as a fee for service.

Biological samples and investigational compounds will be excluded from R&D disclosures. These compounds are subject to provisions under the Clinical Trial Directive (their use is submitted in the clinical trial approval process).

Lending of laboratory equipment that is used exclusively for conducting a study and will be returned to AbbVie at the end of the study will not be disclosed in the R&D aggregate amount.

Date Methodology:
AbbVie followed the date methodology when determining which ToVs are in scope for current reporting cycle:

Paid Date is defined as the date the payment was provided to the covered recipient. ToVs related to the following categories use the Paid Date when determining applicability for current year reporting requirements (e.g., did the payment occur within the reporting period 1 January 2016 to 31 December 2016).

- Research and Development

Note: For the current reporting year, any ToVs with a paid date in 2016 that relates to an event in 2014 will not be reported as the timing of the event occurred prior to the effective date (1 January 2015) of the EFPIA Disclosure Code requirements.

VAT:
Where applicable, disclosure of HCP and HCO payments does not include VAT

Withholding Taxes:
Where applicable, for services provided in locations outside of The Netherlands ToV amounts will be reported as in the contract agreement.

Currency:
All information is reported in Euro

Exchange Rate:
Where transfers of value were captured in foreign currency, amounts were converted to local currency based on Monthly Average Rates.

Rounding:
For each HCP/HCO, ToVs for each reporting category are rounded to the nearest Euro. The Total Amount for each HCP/HCO represents the sum of the reporting category amounts.

Multiyear contacts:
For multiyear contracts, disclosure only includes ToVs applicable during the reporting period (1 January 2016 and 31 December 2016).